

Consolidated Income Statement

Year ended 30 June 2006

	<i>Notes</i>	2006 <i>RMB'000</i>	2005 <i>RMB'000</i> (As restated)
Turnover	5	2,797,707	2,238,454
Cost of sales		(904,146)	(729,719)
Gross profit		1,893,561	1,508,735
Gain arising from changes in fair value less estimated point-of-sale costs of biological assets	20	153,059	175,620
Change in fair value of convertible bonds	32	(5,135)	—
Other revenues	6	116,645	83,793
Selling and distribution expenses		(293,615)	(228,090)
General and administrative expenses		(153,228)	(130,791)
Research expenses		(64,350)	(67,763)
Other operating expenses	8	(160,810)	(89,945)
Profit from operations		1,486,127	1,251,559
Finance costs	9(a)	(193,626)	(75,674)
Share of net profit of associates	24	103,313	121,400
Loss on deemed disposal of interest in associates	24	(37,530)	—
Profit before income tax	9	1,358,284	1,297,285
Income tax	10	(344)	(361)
Profit for the year		1,357,940	1,296,924
Profit attributable to:			
Equity shareholders of the Company	11	1,358,235	1,297,632
Minority interests		(295)	(708)
		1,357,940	1,296,924
Earnings per share for profit attributable to equity shareholders of the Company during the year			
— Basic	12(a)	RMB0.57	RMB0.55
— Diluted	12(b)	RMB0.56	RMB0.54
Dividends	13	272,538	262,364

The notes on pages 46 to 100 form an integral part of these financial statements.